MOTS-C 10 mg

MOTS-c 10 mg contains a mitochondrial-derived peptide studied for its role in metabolic regulation and insulin sensitivity. In preclinical research, it has been investigated for effects on glucose metabolism, mitochondrial function, and exercise performance. A Phase 2a clinical trial is currently evaluating MOTS-c in adults with prediabetes and overweight/obesity. It is not FDA-approved for any human use, and all non-medical use falls outside approved indications.

No established dosing protocol exists for MOTS-c in humans. Community protocols commonly reference doses ranging from 1 mg daily to 5 mg twice weekly, with cycle lengths of 8–12 weeks. These protocols are anecdotal and not supported by clinical evidence. The ongoing Phase 2a trial has not yet reported its dosing protocol.

No. MOTS-c acts on mitochondrial signaling pathways and AMPK activation rather than the hypothalamic-pituitary-gonadal axis. It does not suppress endogenous testosterone production, so post-cycle therapy in the context of testosterone recovery is not applicable. A washout period of 4 weeks between cycles is commonly referenced in community protocols.

MOTS-c is a mitochondrial-derived peptide that acts as a retrograde signaling molecule, communicating mitochondrial metabolic status to the nucleus. It activates AMPK through inhibition of the folate cycle and accumulation of AICAR. In preclinical models, MOTS-c improves insulin sensitivity, enhances mitochondrial bioenergetic performance, and mimics some effects of exercise.

The time course for MOTS-c is not established in humans. In preclinical studies, a single dose of MOTS-c (15 mg/kg) improved exercise performance in mice when tested acutely. Long-term physical activity increased MOTS-c protein expression in skeletal muscle over 4–8 weeks. Human effects and timeframes have not been characterized.

There is no evidence-based “best” mitochondrial peptide. MOTS-c is studied for AMPK-mediated metabolic effects, while SS-31 targets cardiolipin and mitochondrial membrane integrity through a different mechanism. Humanin is another mitochondrial-derived peptide with cytoprotective properties. The appropriate choice depends on research goals and individual circumstances.

MOTS-c is a mitochondrial-derived peptide that activates AMPK and regulates nuclear gene expression. SS-31 is a synthetic tetrapeptide that binds to cardiolipin on the inner mitochondrial membrane, stabilizing mitochondrial structure and reducing oxidative stress. The two have different mechanisms, and some community protocols reference them in combination.

Both are mitochondrial-derived peptides, but they have different primary mechanisms. MOTS-c is studied for metabolic regulation through AMPK activation, while Humanin is investigated for cytoprotective and neuroprotective effects. They are sometimes referenced together in research contexts for their complementary mitochondrial functions.

The 10 mg vial strength provides flexibility for reconstitution and dosing. Community protocols reference a range from 1 mg to 10 mg per week. Preclinical animal studies have used doses of 5–15 mg/kg, which would translate to much higher human-equivalent doses. Because no human dosing has been established, the appropriate amount should be based on research context rather than a fixed protocol.

MOTS-c 10 mg is labeled at 10 mg of MOTS-c per vial. It is supplied as a lyophilized powder in a 2 mL vial, requiring reconstitution before use.

No published laboratory report is currently available for this specific product. Product potency and purity verification would apply to tested samples only and should not be interpreted as a measurement of every vial or production batch.

Lyophilized MOTS-c is typically reconstituted with a suitable solvent such as Bacteriostatic Water or sterile water. The volume of solvent added determines the concentration of the resulting solution. Proper sterile technique should be used during reconstitution.